Investigational drug · Phase 2
BI 3000202
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Systemic Lupus Erythematosus.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
9
Any phase or sponsor naming "BI 3000202"
First trial start
2026
Apr 20, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BI 3000202", any sponsor or status.
Conditions studied
As listed on its trial records.
- Systemic Lupus Erythematosus
Approved drugs for the same conditions: Lupus (SLE) · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "BI 3000202" as an intervention, largest first.
- A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)Pivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07409181 · 405 participants (planned) · Start Apr 20, 2026 · Primary completion Feb 4, 2029
Drug: BI 3000202; Placebo · For: Systemic Lupus Erythematosus
Sites: Beverly Hills, California; La Palma, California; San Diego, California · 139 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT05945888 · 68 participants · Start Jul 25, 2023 · Primary completion Nov 13, 2023
Drug: BI 3000202; Placebo matching BI 3000202 · For: Healthy
Sites: Biberach, Germany
Boehringer IngelheimBoehringer Ingelheim
NCT06327256 · 40 participants · Start Apr 9, 2024 · Primary completion Sep 27, 2024
Drug: BI 3000202; Placebo and 1 more · For: Healthy
Sites: Edegem, Belgium
- A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver ProblemsCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT07486102 · 34 participants · Start May 1, 2026 · Primary completion Oct 30, 2026
Drug: BI 3000202 · For: Healthy; Hepatic Impairment
Sites: San Antonio, Texas
- A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 InterferonopathiesActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06878365 · 16 participants · Start Jul 29, 2025 · Primary completion Dec 10, 2029
Drug: BI 3000202_low dose; BI 3000202_high dose · For: Type 1 Interferonopathies
Sites: San Francisco, California; Philadelphia, Pennsylvania; Houston, Texas · 20 sites in all
- A Study in Healthy Men to Test Whether Esomeprazole Influences the Amount of BI 3000202 in the BloodCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT06419660 · 15 participants · Start May 22, 2024 · Primary completion Jul 8, 2024
Drug: BI 300202; esomeprazole · For: Healthy
Sites: Biberach, Germany
Boehringer IngelheimBoehringer Ingelheim
NCT07215260 · 14 participants · Start Nov 5, 2025 · Primary completion Dec 7, 2025
Drug: BI 3000202; Rosuvastatin and 1 more · For: Healthy
Sites: Biberach, Germany
- A Study in Healthy Men and Women to Test How BI 3000202 is Taken up and Processed by the BodyCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT07273474 · 12 participants · Start Dec 30, 2025 · Primary completion Mar 5, 2026
Drug: BI 3000202; BI 3000202 [14C]-labelled · For: Healthy
Sites: Groningen, Netherlands
Boehringer IngelheimBoehringer Ingelheim
NCT07774325 · 10 participants · Start Sep 1, 2026 · Primary completion Oct 11, 2026
Drug: BI 3000202; Ciclosporin and 1 more · For: Healthy
Sites: Biberach, Germany
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Systemic Lupus Erythematosus
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- FrexalimabSAR441344Phase 39 trials
Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
- CM313Phase 36 trials
Keymed Biosciences Co.Ltd · Systemic Lupus Erythematosus, Primary Immune Thrombocytopenia, Platelet Transfusion Refractoriness
- EnpatoranM5049, M5049 dosePhase 35 trials
EMD Serono Research & Development Institute, Inc. · Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus
- MIL62Phase 34 trials
Beijing Mabworks Biotech Co., Ltd. · Systemic Lupus Erythematosus, Neuromyelitis Optica Spectrum Disorder, Primary Membranous Nephropathy
- ObexelimabPhase 34 trials
Zenas BioPharma (USA), LLC · Systemic Lupus Erythematosus, Warm Autoimmune Hemolytic Anemia, Relapsing Multiple Sclerosis
- Rese-celCABA-201Phase 34 trials
Cabaletta Bio · Pemphigus Vulgaris, Systemic Sclerosis, Scleroderma
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Boehringer Ingelheim.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.